

Potential Role of PARP Inhibition in the Management of Breast Cancer


Rita Nanda, MD

Research To Practice ASCO 2017 Symposium June 5, 2017

Disclosures

Advisory Committee	Celgene Corporation, Pfizer Inc		
Contracted	Celgene Corporation, Genentech BioOncology,		
Research	Merck		

How much of breast cancer is hereditary?



- Sporadic cancer (70%)
 - By chance
- Familial cancer (15-20%)
 - Environment + genes
- Hereditary cancer (10%)
 - Inherited DNA mutation

When to suspect a hereditary syndrome

- Early onset breast cancer
- Bilateral breast cancer/multiple cancers
- Multiple family members/generations with cancer
- Clustering of certain cancers in family
- Rare cancers
- Populations with certain cancer gene mutations (e.g., Ashkenazi Jewish)
- Tumor mutation testing suggesting possible germline mutation

Indications for testing-NCCN guidelines


 Individual from a family with a known deleterious BRCA1/BRCA2 Personal history of breast cancer^b + one or more of the following: Diagnosed ≤45 y Diagnosed ≤50 y with: An additional breast cancer primary^c ◊ ≥1 close blood relative^d with breast cancer at any age ◊ ≥1 close relative with pancreatic cancer ◊ ≥1 relative with prostate cancer (Gleason score ≥7) An unknown or limited family history^a Diagnosed ≤60 y with: O Triple negative breast cancer Diagnosed at any age with: ◊ ≥2 close blood relatives with breast cancer, pancreatic cancer or prostate cancer (Gleason score ≥7) at any age ◊ ≥1 close blood relative^d with breast cancer diagnosed ≤50 y ◊ ≥1 close blood relative^d with ovarian^e carcinoma **A close male blood relatived with breast cancer** ◊ For an individual of ethnicity associated with higher mutation frequency (eg, Ashkenazi Jewish) no additional family history may be required^f

- Personal history of ovarian^o carcinoma
- · Personal history of male breast cancer

NCCN Guidelines Version 1.2017 BRCA-Related Breast and/or Ovarian Cancer Syndrome

- Personal history of prostate cancer (Gleason score ≥7) at any age with ≥1 close blood relative^d with ovarian carcinoma at any age or breast cancer ≤50 y or two relatives with breast, pancreatic, or prostate cancer (Gleason score ≥7) at any age
- Personal history of pancreatic cancer at any age with ≥1 close blood relative^d with ovarian carcinoma at any age or breast cancer ≤50 y or two relatives with breast, pancreatic cancer, or prostate cancer (Gleason score ≥7) at any age
- Personal history of pancreatic cancer and Ashkenazi Jewish ancestry
- BRCA1/2 mutation detected by tumor profiling in the absence of germline mutation analysis
- Family history only (significant limitations of interpreting test results for an unaffected individual should be discussed):
- First- or second-degree blood^d relative meeting any of the above criteria
- Third-degree blood^d relative who has breast cancer^b and/or ovarian^e carcinoma and who has ≥2 close blood relatives^d with breast cancer (at least one with breast cancer ≤50 y) and/or ovarian^e carcinoma

Testing Options and Cost



Panel Testing

- Pros
 - Can test for multiple genes in single test
 - Cost effective
 - Time saving
 - Improved detection rate in families with atypical presentations
- Cons
 - Incidental findings-don't fit family history
 - Mutations in genes of limited clinical utility
 - High rate of VUSs

Phase 2 studies of olaparib reported to date

	Study 8 ¹	Study 20 ²	Study 42 ³
Patient population	Locally advanced/metastatic BRCAm BC, ≥1 chemotherapy regimen	Advanced metastatic or recurrent BC, triple negative or known <i>BRCA</i> m	Advanced <i>BRCA</i> m BC that progressed despite ≥3 previous lines of chemotherapy for advanced/metastatic disease
Prior lines of therapy for advanced disease	3 chemotherapy regimens (median)	3 chemotherapy regimens (median)	4.6 (mean)
ORR	41%	0% (50% unconfirmed in BRCAm)	13%
CBR	56%	38% (in <i>BRCA</i> m)	60%
Median DoR	144 days	-	204 days


	Olaparib 400mg twice daily (n=27)			
	<i>BRCA1</i> (n=18)	<i>BRCA2</i> (n=9)	Triple Negative (n=13)	Non-triple Negative (n=14)
Objective Response	9 (50%)	2 (22%)	7 (54%)	4 (29%)
Complete Response	1 (6%)	0	0	0
Partial Response	8 (44%)	2 (22%)	7 (54%)	4 (29%)

Early studies demonstrated evidence of activity of olaparib monotherapy in heavily pretreated gBRCA-associated MBC

1. Tutt A, et al. Lancet. 2010;376:235-244. 2. Gelmon KA et al. Lancet Oncol. 2011;12:852-861. 3. Kaufman B, et al. J Clin Oncol. 2015;33:244-250.

OlympiAD study design

- HER2-negative metastatic BC
 - ER+ and/or PR+ or TNBC
- Deleterious or suspected deleterious gBRCAm
- Prior anthracycline and taxane
- ≤2 prior chemotherapy lines in metastatic setting
- HR+ disease progressed on ≥1 endocrine therapy, or not suitable
- If prior platinum use
 - No evidence of progression during treatment in the advanced setting
 - ≥12 months since (neo)adjuvant treatment



Primary endpoint:

 Progression-free survival (RECIST 1.1, BICR)

Secondary endpoints:

- Time to second progression or death
- Overall survival
- Objective response rate
- Safety and tolerability
- Global HRQoL (EORTC-QLQ-C30)


BICR, blinded independent central review; ER, estrogen receptor; HR, hormone receptor; HRQoL, health-related quality of life; PR, progesterone receptor; RECIST, response evaluation criteria in solid tumors; TNBC, triple negative breast cancer

Presented by: Mark Robson, MD

6/4/2017

PRESENTED AT: ASCO ANNUAL MEETING '17 #ASCO17 Slides are the property of the author. Permission required for reuse.

Primary endpoint: progression-free survival by BICR




Presented by: Mark Robson, MD

PRESENTED AT: ASCO ANNUAL MEETING '17 #ASCO17

6/4/2017

Slides are the property of the author. Permission required for reuse.

Time to second progression or death (PFS2) by investigator assessment




Presented by: Mark Robson, MD

PRESENTED AT: ASCO ANNUAL MEETING '17 #ASCO17 Slides are the property of the author. Permission required for reuse.

6/4/2017

Objective response by BICR




Presented by: Mark Robson, MD

PRESENTED AT: ASCO ANNUAL MEETING '17 #ASCO17 Slides are the property of the author. Permission required for reuse.

6/4/2017

BRIGHTNESS Study Design



= Last dose of veliparib/placebo + carboplatin/placebo + paclitaxel

^a Performed at least 2 weeks after last chemotherapy treatment.

^b Surgery (+/- radiotherapy) was recommended approximately 2–8 weeks after last chemotherapy treatment,

Study Objectives

Primary objectives:

• pCR

Secondary objectives:

• EFS, OS, breast conservation rate

Tertiary objectives:

• MRI, near pCR, QoL


Presented by: Charles E. Geyer

PRESENTED AT: ASCO ANNUAL MEETING '17 #ASCO17


Slides are the property of the author. Permission required for reuse.

Efficacy

- Addition of veliparib and carbo significantly improved pCR over control (53.2% vs 31.0%, *p*<0.001) confirming results of I-SPY-2.
- Addition of veliparib to carbo/paclitaxel did not demonstrate improvement in pCR compared to carbo/paclitaxel arm (53.2% vs 57.5%, p=0.36).
- Increase in pCR with addition of carboplatin was independent of gBRCA mutation status.



Intent to Perform a Breast Conserving Surgery




Minimal Residual Disease Residual Cancer Burden Class 0 or I p<0.001 100 p=0.74 75 Patients 50-25. 68.3 47.2 70.0 Ω V+Cb+P Cb+P Р n=125 n=268 n=140

PRESENTED AT: ASCO ANNUAL MEETING '17 #ASCO17 Slides are the property of the author. Permission required for reuse.

Presented by: Charles E. Geyer


Background – Talazoparib

Talazoparib is a highly potent inhibitor of PARP¹



PRESENTED AT: ASCO ANNUAL MEETING '17 #ASCO17

Phase 1 trial – 18 breast cancer patients with BRCA1/2 germline mutations²



Graph shows percentage change in target lesion for patients undergoing treatment with talazoparib who have gBRCA breast cancer. Positive values indicate tumor growth, negative values indicate tumor reduction, and the dashed line represents the definition of partial response from RECIST guidelines. Patients from parts 1 and 2 of the trial are included. Abbreviation: SLD, sum of longest diameter.

Confidential / Under ASCO Embargo

1. Lord CJ, Ashworth A. Science. 2017;355:1152-1158; 2. de Bono J et al. Cancer Discov. 2017 Feb 27. doi: 10.1158/2159-8290.CD-16-1250.

Presented by: Nicholas C. Turner

Slides are the property of the author. Permission required for reuse.

ABRAZO Phase 2 Clinical Trial – Key Eligibility Criteria

- Patients with advanced breast cancer who carry a deleterious or suspected deleterious germline *BRCA1/2* mutation (by central laboratory or a local report approved by the sponsor)
 - Cohort 1: PR or CR to last platinum-containing regimen for metastatic disease with disease progression
 > 8 weeks following the last dose of platinum
 - Cohort 2: 3 or more prior cytotoxic regimens for metastatic disease; no prior platinum for metastatic disease
- Measurable disease by RECIST v1.1
- ECOG performance status 0 or 1

Slides are the property of the author. Permission required for reuse.

Adequate organ and bone marrow function

ASCO ANNUAL MEETING '17 | #ASCO17

- CNS metastases permitted, provided stable following local therapy
- HER2+ breast cancer permitted, provided the patient's disease is refractory to HER2-targeted therapy
- Washout from prior therapy (systemic therapy, RT, surgery): 14 days

Abbreviations: CNS, central nervous system; CR, complete response; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors version 1.1; RT, radiation therapy.

Presented by: Nicholas C. Turner

Confidential / Under ASCO Embargo

Primary Efficacy Endpoint – ORR by Independent Radiologist Facility

	Cohort 1 Prior Platinum (n = 48)	Cohort 2 3L+, No Prior Platinum (n = 35)	Total (N = 83)
Objective response rate, % (95% CI)	21 (10-35)	37 (22-55)	28 (18-39)
Best overall response, % (No.)			
Complete response	4 (2)	0	2 (2)
Partial response	17 (8)	37 (13)	25 (21)
Stable disease	38 (18)	51 (18)	43 (36)
Progressive disease	38 (18)	11 (4)	27 (22)
Not evaluable	4 (2)	0	2 (2)

Similar RR in BRCA1 vs BRCA2 (23% vs 33%) Similar RR in TNBC vs non-TNBC (26% vs 29%)

Presented by: Nicholas C. Turner

PRESENTED AT: ASCO ANNUAL MEETING '17 #ASCO17 Slides are the property of the author. Permission required for reuse.

Confidential / Under ASCO Embargo

Select ongoing trials of PARPi in advanced breast cancer

Name	Phase	Arms	Eligibility	Clinicaltrials.gov
BROCADE	Ш	paclitaxel/carbo +/- veliparib	• gBRCA1/2	NCT02163694
BRAVO	Ш	niraparib vs TPC	• gBRCA1/2	NCT01905592
S1416	II	cisplatin +/-veliparib	gBRCA1/2TNBC	NCT02595905
TBB	П	talazoparib	HRD highgHR/sHR mutation	NCT02401347
Ruby	II	rucaparib	BRCAnesssBRCA1/2 mutation	NCT02505048
TOPACIO	Ш	niraparib + pembrolizumab	TNBCOvCa	NCT02657889

Select ongoing neoadjuvant/adjuvant trials of PARPi in breast cancer

Name	Phase	Arms	Clinicaltrials.gov
ISPY2	Ш	paclitaxel → AC irinotecan + talazoparib → AC	NCT01042379
MDACC	П	talazoparib x 6 mos	NCT02282345
NSABP B-55 (OlympiA)	Ш	olaparib vs placebo x 1 year	NCT02032823

Thank You!